http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June (Abstract #11024). http://medicalxpress.com/news/2013-05-parp-inhibitor-pancreatic-prostate-cancers.html Cancer Wed, 15 May 2013 18:00:01 EST news287856979 In a recent study, scientists have concluded that the cure rates of Miltefosine, the only oral drug for visceral leishmaniasis available, have significantly decreased. Miltefosine was introduced in the Indian subcontinent a decade ago. Despite adhering to the treatment, only 3 out of 4 patients treated with Miltefosine in Nepal today are being cured. http://medicalxpress.com/news/2013-03-kala-azar-treatment-nepal.html Diseases, Conditions, Syndromes Fri, 01 Mar 2013 10:47:40 EST news281357253 Treatment with a newer antibiotic, tedizolid phosphate, once daily for 6 days was statistically noninferior (no worse than) in efficacy to the antibiotic linezolid twice daily for 10 days for both early (at day 2 to 3) and sustained (at day 11) clinical responses in patients with acute bacterial skin and skin structure infections, according to a study appearing in the February 13 issue of JAMA. http://medicalxpress.com/news/2013-02-shorter-course-antibiotic-similar-effectiveness-skin.html Diseases, Conditions, Syndromes Tue, 12 Feb 2013 16:30:02 EST news279906626 An experimental oral drug given to mice after a spinal cord injury was effective at improving limb movement after the injury, a new study shows. http://medicalxpress.com/news/2013-01-oral-drug-spinal-cord-injury.html Neuroscience Tue, 08 Jan 2013 17:00:06 EST news276874749 Huntsman Cancer Institute (HCI) researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic lymphoma (Ph+ ALL). The New England Journal of Medicine released results of the trial today. http://medicalxpress.com/news/2012-11-clinical-trial-good-results-leukemia.html Cancer Fri, 30 Nov 2012 09:10:17 EST news273489005 A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial. http://medicalxpress.com/news/2012-11-drug-resistance-patients-rare-sarcoma.html Cancer Wed, 21 Nov 2012 18:30:09 EST news272740107 Watch where you jump in for a swim or where your bath water comes from, especially if you live in Africa, Asia or South America. Snails that live in tropical freshwater in these locations are intermediaries between disease-causing parasitic worms and humans. http://medicalxpress.com/news/2012-11-treatment-snail-borne-schistosomiasis-haul.html Diseases, Conditions, Syndromes Tue, 20 Nov 2012 07:59:04 EST news272620734 (Medical Xpress)—According to the Centers for Disease Control (CDC), endometriosis, a gynecological disorder in which cells from the uterus lining grow in other areas of the body, is the number one reason for a hysterectomy in women ages 18-35.  Current treatment options for endometriosis are severely limited by side effects of existing medications and surgical options have more risks.  A nationwide clinical trial is testing an investigational drug as a potential new option for patients with moderate to severe pain from this disease.  http://medicalxpress.com/news/2012-10-potential-drug-pain-symptoms-endometriosis.html Obstetrics & gynaecology Tue, 09 Oct 2012 09:30:14 EST news268993806 New research proves the validity of one of the most promising approaches for combating Alzheimer's disease (AD) with medicines that treat not just some of the symptoms, but actually stop or prevent the disease itself, scientists are reporting. The study, in the journal ACS Medicinal Chemistry Letters, also identifies a potential new oral drug that the scientists say could lead the way. http://medicalxpress.com/news/2012-10-evidence-easing-inflammation-brain-cells.html Alzheimer's disease & dementia Wed, 03 Oct 2012 14:50:25 EST news268494610 (AP) — The Food and Drug Administration on Monday approved the first drug shown to reduce the risk of HIV infection, the latest milestone in the 30-year battle against the virus that causes AIDS. http://medicalxpress.com/news/2012-07-truvada-pill-hiv.html HIV & AIDS Mon, 16 Jul 2012 13:08:13 EST news261662862 Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients. http://medicalxpress.com/news/2012-05-benefit-maintenance-therapy-multiple-myeloma.html Cancer Fri, 11 May 2012 15:13:34 EST news255968004 An investigational oral drug called ONO-4641 reduced the number of lesions in people with multiple sclerosis (MS), according to the results of a phase two clinical trial to be presented as Emerging Science (formerly known as Late-Breaking Science) at the American Academy of Neurology's 64th Annual Meeting in New Orleans April 21 to April 28, 2012. http://medicalxpress.com/news/2012-04-ono-pill-ms-lesions-phase.html Neuroscience Mon, 16 Apr 2012 16:00:03 EST news253810569 Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4. http://medicalxpress.com/news/2012-04-early-clinical-galeterone-safe-effective.html Cancer Sun, 01 Apr 2012 05:57:35 EST news252478648 Programs to prevent or delay type 2 diabetes in high-risk adults would result in fewer people developing diabetes and lower health care costs over time, researchers conclude in a new study funded by the National Institutes of Health. http://medicalxpress.com/news/2012-03-interventions-diabetes-good-investment.html Diabetes Thu, 22 Mar 2012 15:00:01 EST news251637033 A new study suggests that administering FTY720, an oral drug that has shown promise in trials for human multiple sclerosis, significantly improves locomotor recovery in mice with spinal cord injury (SCI). The research suggests a possible new avenue to counteract the degeneration of the spinal cord in human SCI. The study will be published in the April 2012 issue of The American Journal of Pathology. http://medicalxpress.com/news/2012-03-therapeutic-approach-spinal-cord-injury.html Diseases, Conditions, Syndromes Tue, 13 Mar 2012 04:22:11 EST news250831279 A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease. http://medicalxpress.com/news/2011-10-oral-drug-relapses-multiple-sclerosis.html Medications Thu, 06 Oct 2011 10:22:22 EST news237115307 A combination of an oral drug, called sorafenib, and a method for injecting microbeads of chemotherapy directly into tumors has been proven safe for liver cancer patients and may improve outcomes for those who have these fast-growing, deadly tumors whose numbers are on the rise in the U.S. http://medicalxpress.com/news/2011-09-micro-chemo-cancer-pill-combo-liver.html Cancer Fri, 30 Sep 2011 17:13:56 EST news236621623 MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs. http://medicalxpress.com/news/2011-09-powerful-diff-treatment.html Diseases, Conditions, Syndromes Mon, 19 Sep 2011 15:49:59 EST news235666182